Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16–17 Years of Age
2.5 × 1010 vp Ad26.COV2.S elicited robust SARS-CoV-2-specific antibody responses in adolescents through 6 months, with acceptable safety and reactogenicity profiles. Compared with adults immunized with 5 × 1010 vp Ad26.COV2.S, adolescents had higher antibody levels, despite being vaccinated with a lower dose.
Authors
- Nathalie Vaissière
- Hanneke Schuitemaker (ORCID: https://orcid.org/0000-0001-8563-2266)
- Jenny Hendriks (ORCID: https://orcid.org/0009-0008-8191-6200)
- Gert C. Scheper (ORCID: https://orcid.org/0000-0003-2316-756X)
- Jerald Sadoff (ORCID: https://orcid.org/0000-0002-4839-3013)
- Macaya Douoguih (ORCID: https://orcid.org/0000-0002-2707-5729)
- Anne Marit de Groot (ORCID: https://orcid.org/0000-0002-4782-3392)
- Frank Struyf (ORCID: https://orcid.org/0000-0001-9988-0260)
- Javier Ruiz‐Guiñazú (ORCID: https://orcid.org/0000-0001-6941-3100)
- Carla Truyers
- Vicky Cárdenas
- Mathieu Le Gars
Institutions
- Janssen (Belgium) (BE)
- Springhouse (US)
- Janssen (United States) (US)
- Janssen (Netherlands) (NL)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1093/jpids/piae098
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Yale University
- National Institutes of Health
- Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University
- Biomedical Advanced Research and Development Authority
- Janssen Pharmaceuticals